Effectiveness and safety of biologics in short-term reaching-standard treatment of moderate to severe atopic dermatitis:a mesh meta analysis
10.3969/j.issn.1671-8348.2024.11.023
- VernacularTitle:生物制剂对中重度特应性皮炎短期达标治疗的有效性和安全性网状meta分析
- Author:
Pingjuan CHEN
1
;
Gaiqiang CAI
;
Ruigui LIU
;
Yongxian MAI
Author Information
1. 中山市小榄人民医院药学部,广东中山 528415
- Keywords:
biologics;
moderate to severe atopic dermatitis;
reaching-standard treatment;
short-term
- From:
Chongqing Medicine
2024;53(11):1717-1725
- CountryChina
- Language:Chinese
-
Abstract:
Objective To employ the mesh meta analysis to compare the effectiveness and safety of short-term reaching-standard treatment in the patients with moderate to severe atopic dermatitis among the different biologics.Methods The randomized controlled trials (RCT) were retrieved from the databases of CNKI,Chinese Biomedical Literature Database,Wanfang,VIP,PubMed,Cochrane Library and Embase data-bases.The retrieval time was from the database establishment to August,2023.The related literatures on the biologics for treating moderate to severe atopic dermatitis were collected.The literatures were screened by the inclusion and exclusion standards,the literature quality was evaluated and the data were extracted.Then the mesh meta analysis was performed by using RevMan 5.3 and Stata 16.0 softwares.Results A total of 754 ar-ticles were retrieved,and 11 articles were finally included,involving in 14 RCT with a total sample number of 5528 cases.There were 4 intervention methods,including placebo and 3 kinds of drugs.The drugs were Dupi-lumab,Lebrikizumab and Tralokinumab.The results showed that for each of effectiveness indicator,different medication regimens had different performance,after comprehensively meeting the treatment criteria,Dupri-uliumab was superior to Lebrikizumab,and Lebrikizumab was superior to Tralokinumab.There was no statis-tical difference in adverse reactions between the three drugs and placebo (P>0.05).Conclusion Dupilumab is currently the most effective biologic agent for short-term target treatment,capable of reducing inflamma-tion and improving skin symptoms.Future studies should further evaluate its long-term efficacy and safety to guide clinical application.
